Inpatient Payment Rule Provides No New Tech Add-On Payments For Devices
This article was originally published in The Gray Sheet
Executive Summary
Medtronic Sofamor Danek's InFuse bone graft/LT-Cage lumbar tapered fusion system does not qualify for a new technology add-on payment under the inpatient prospective payment system (IPPS) fiscal 2003 final rule because the device is FDA-approved only for single-level spinal fusion
You may also be interested in...
Lessons Learned: Medtronic Advises On New Tech Add-On Payment Process
Device firms applying for a new technology "add-on" payment should take steps to include Medicare beneficiaries in their clinical trials, according to Medtronic Sofamor Danek Reimbursement Group Director Robert Peterson
Lessons Learned: Medtronic Advises On New Tech Add-On Payment Process
Device firms applying for a new technology "add-on" payment should take steps to include Medicare beneficiaries in their clinical trials, according to Medtronic Sofamor Danek Reimbursement Group Director Robert Peterson
First Device Qualifies For Add-On Payment; CMS Retains Proposed Threshold
The device industry's hopes to reduce the Centers for Medicare & Medicaid Services' new technology "add-on" payment threshold are riding on a provision in the House's "Medicare Prescription Drug & Modernization Act" of 2003 (HR 1)